You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation, reports the company. A successful kidney transplantation of an HLA sensitized patient has been accomplished following desensitization with the candidate drug IdeS at Uppsala University Hospital. “We have demAlready a subscriber Login You have read all your free articles,…
BioInvent International announces that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma. The decision follows BioInvent’s review and discussion with the US Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016.Already a subscriber Login You have…
XNK Therapeutics has announced that the first patient has been treated in a Phase II clinical study using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab). “Having the first patient treated with NK cAlready a subscriber Login You have read all…
Ultimovacs has announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company’s Tetanus-Epitope Targeting (TET)-platform. The platform allows for the production of multiple therapeutic cancer vaccines that can be used to stAlready a subscriber Login You have read…
